Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma

Sundar Jagannath, Meletios A. Dimopoulos, Sagar Lonial

Research output: Contribution to journalReview articlepeer-review

52 Scopus citations

Abstract

Multiple myeloma (MM) is an incurable disease characterized by the accumulation of malignant plasma cells in the bone marrow. Recently, an improved understanding of the biology of the disease has led to the development of targeted agents such as the proteasome inhibitor bortezomib and the immunomodulatory agents thalidomide and lenalidomide; however, MM remains incurable. The combination of bortezomib and an HDAC inhibitor synergistically induces MM cell apoptosis and may be of value in the treatment of patients with relapsed/refractory MM. This review examines the potential of combined proteasome and HDAC inhibition in the treatment of relapsed/refractory MM.

Original languageEnglish
Pages (from-to)1111-1118
Number of pages8
JournalLeukemia Research
Volume34
Issue number9
DOIs
StatePublished - Sep 2010
Externally publishedYes

Keywords

  • Bortezomib
  • Histone deacetylase inhibitor
  • Multiple myeloma
  • Proteasome inhibitor
  • Vorinostat

Fingerprint

Dive into the research topics of 'Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma'. Together they form a unique fingerprint.

Cite this